US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Scribe Therapeutics, Inc.

31.01

+2.579.02%

Volume:115.40K

Turnover:3.39M

Market Cap:544.99M

PE:-14.04

High:31.61

Open:28.26

Low:27.20

Close:28.44

52wk High:39.60

52wk Low:17.31

Shares:17.58M

Float Shares:8.62M

Volume Ratio:0.49

T/O Rate:1.34%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2080

EPS(LYR):-8.9776

ROE:--

ROA:--

PB:-3.43

PE(LYR):-3.45

Loading ...

Overview Company News Filings

Scribe Therapeutics Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $60

THOMSON REUTERS

U.S. Research Roundup-Adobe, Braveheart Bio, CACI International

Top Premarket Gainers

MT Newswires Live

Analysts’ Top NA Picks: Harrow Health (HROW), Scribe Therapeutics Inc. (SCTX)

Leerink starts Scribe Therapeutics at Outperform on X-editor platform

Scribe Therapeutics Inc Price Target Announced at $50.00/Share by Guggenheim

Guggenheim Initiates Scribe Therapeutics at Buy With $50 Price Target

MT Newswires Live

Leerink Partners Initiates Scribe Therapeutics at Outperform With $37 Price Target

MT Newswires Live

Wells Fargo Initiates Scribe Therapeutics at Overweight With $60 Price Target

MT Newswires Live

Scribe Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

Scribe's Genetic Editing Aims to Prevent Heart Attacks

Insiders Double Down as Big Money Pours Into Scribe Therapeutics

OrbiMed Advisors Acquires 1,000,000 Scribe Therapeutics Shares Valued at $15 Million

Scribe Therapeutics CFO David Parrot Reports $ 39,990 Common Stock Acquisition

Scribe Therapeutics Updates Governance Following Initial Public Offering

Scribe Therapeutics Adopts Amended and Restated Bylaws Effective at IPO Close

Press Release: Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

Opening Day: Scribe Therapeutics makes strong trading debut

Top Midday Gainers

MT Newswires Live

Scribe Therapeutics Shares Rise in Nasdaq Debut

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/SCTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SCTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCTX\",,,,,undefined,":{"symbol":"SCTX","market":"US","secType":"STK","nameCN":"Scribe Therapeutics, Inc.","latestPrice":31.005,"timestamp":1788201449500,"preClose":28.44,"halted":0,"volume":115400,"delay":0,"changeRate":0.09018987341772143,"floatShares":8623940,"shares":17577400,"eps":-2.208,"marketStatus":"Trading","change":2.565,"latestTime":"08-31 14:37:59 EDT","open":28.26,"high":31.6074,"low":27.2,"amount":3393947.466,"amplitude":0.154972,"askPrice":31.24,"askSize":28,"bidPrice":30.42,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-2.208,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788206400000},"marketStatusCode":2,"adr":0,"listingDate":1784865600000,"exchange":"NASDAQ","adjPreClose":28.44,"preHourTrading":{"tag":"盘前","latestPrice":28.1,"preClose":28.44,"latestTime":"09:13 EDT","volume":246,"amount":6999.39372,"timestamp":1788182005787,"change":-0.34,"changeRate":-0.011955,"amplitude":0.085091},"postHourTrading":{"tag":"盘后","latestPrice":28,"preClose":28.44,"latestTime":"19:30 EDT","volume":197,"amount":5575.81,"timestamp":1787959806464,"change":-0.44,"changeRate":-0.015471,"amplitude":0.015471},"volumeRatio":0.485619},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCTX\",,,,,undefined,":{"symbol":"SCTX","floatShares":8623940,"roa":"--","roe":"--","lyrEps":-8.977559,"volumeRatio":0.485619,"shares":17577400,"dividePrice":0,"high":31.6074,"amplitude":0.154972,"preClose":28.44,"low":27.2,"week52Low":17.305,"pbRate":"-3.43","psRate":"15.02","week52High":39.6,"institutionHeld":0,"latestPrice":31.005,"committee":0.945525,"eps":-2.208,"divideRate":0,"volume":115400,"delay":0,"ttmEps":-2.208,"open":28.26,"prevYearClose":15,"prevWeekClose":28.44,"prevMonthClose":19.48,"prevQuarterClose":15,"fiveDayClose":37.25,"twentyDayClose":20.835,"sixtyDayClose":15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SCTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SCTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SCTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1787889600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SCTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SCTX","date":"2026-08-28","current":-14.04212,"percent":0.24,"low":-19.666901,"twenty":-16.393484,"median":-12.262115,"eighty":-10.284865,"high":-6.340558,"avg":-12.735734,"sd":3.229786,"marketCap":544048892},"quantilePoints":[{"date":"2026-07-24","current":-7.393791,"twenty":-7.183144,"median":-6.867174,"eighty":-6.551205,"marketCap":264180150},{"date":"2026-07-31","current":-10.770598,"twenty":-10.0156,"median":-9.614342,"eighty":-7.393791,"marketCap":384833474},{"date":"2026-08-07","current":-13.41573,"twenty":-11.647029,"median":-10.284865,"eighty":-9.535147,"marketCap":479344048},{"date":"2026-08-14","current":-10.754759,"twenty":-12.565698,"median":-10.885431,"eighty":-9.693538,"marketCap":384267542},{"date":"2026-08-21","current":-17.333272,"twenty":-13.41573,"median":-11.187695,"eighty":-10.0156,"marketCap":619317792},{"date":"2026-08-28","current":-15.226669,"twenty":-16.393484,"median":-12.262115,"eighty":-10.284865,"marketCap":544048892}],"updateTime":1788201479101},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SCTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663074889","title":"Scribe Therapeutics Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2663074889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663074889?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:10","pubTimestamp":1788171056,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nAZN4THCX4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SCTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663020059","title":"U.S. Research Roundup-Adobe, Braveheart Bio, CACI International","url":"https://stock-news.laohu8.com/highlight/detail?id=2663020059","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663020059?lang=en_us&edition=fundamental","pubTime":"2026-08-31 15:24","pubTimestamp":1788161046,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI InternationalAug 31 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adob","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL4N44S0J8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUNR","ADBE","RKLB","ATI","DE","PTGX","MADE","XTL","TPZ","FTAG","CIEN","DLTR","BRCC","AFRM","ATTO","BW","AIRJ","HWAY","BPOP","IBM","PYPL","RBRK","RVMD","AFRU","FIVN","SCTX","ETR","PATH","ADSK","MDB","ASST","HQY","OHI","BURL","CRM","BAC","CACI","BRVE","SBRA","TROW","PCG","BILT","SRE","BCDF","RDW","EIX","HONA","ANF","KALU","ICE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661734422","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2661734422","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661734422?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:13","pubTimestamp":1787570029,"startTime":"0","endTime":"0","summary":"Sadot (SDOT) shares were up more than 52% in Monday's premarket activity following a 56% rise in Friday's session.Picard Medical (PMI) stock was 40% higher after a 5.9% increase at the prior closing w","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CYPH","BK4189","SCTX","LU1043141123.HKD","LU0426412945.USD","HVII","BK4209","LU0426417589.USD","LU0994945656.USD","BK4082","BK4139","LU0545562505.USD","SDOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660233958","title":"Analysts’ Top NA Picks: Harrow Health (HROW), Scribe Therapeutics Inc. (SCTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660233958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660233958?lang=en_us&edition=fundamental","pubTime":"2026-08-20 23:00","pubTimestamp":1787238021,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Harrow Health (HROW) and Scribe Therapeutics Inc. (SCTX) wit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-na-picks-harrow-health-hrow-scribe-therapeutics-inc-sctx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-na-picks-harrow-health-hrow-scribe-therapeutics-inc-sctx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NA","SCTX","BK4141","BK4007","BK4139","BK4557","HROW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660996594","title":"Leerink starts Scribe Therapeutics at Outperform on X-editor platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2660996594","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660996594?lang=en_us&edition=fundamental","pubTime":"2026-08-19 01:10","pubTimestamp":1787073010,"startTime":"0","endTime":"0","summary":"As previously reported, Leerink initiated coverage of Scribe Therapeutics (SCTX) with an Outperform rating and $37 price target The firm views Scri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/leerink-starts-scribe-therapeutics-at-outperform-on-x-editor-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/leerink-starts-scribe-therapeutics-at-outperform-on-x-editor-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SOCL","SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660467839","title":"Scribe Therapeutics Inc Price Target Announced at $50.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2660467839","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660467839?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:32","pubTimestamp":1787056320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SCTX/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660699844","title":"Guggenheim Initiates Scribe Therapeutics at Buy With $50 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2660699844","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660699844?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:25","pubTimestamp":1787048701,"startTime":"0","endTime":"0","summary":"(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660987469","title":"Leerink Partners Initiates Scribe Therapeutics at Outperform With $37 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2660987469","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660987469?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:24","pubTimestamp":1787048693,"startTime":"0","endTime":"0","summary":"Leerink Partners Initiates Scribe Therapeutics at Outperform With $37 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660654484","title":"Wells Fargo Initiates Scribe Therapeutics at Overweight With $60 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2660654484","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660654484?lang=en_us&edition=fundamental","pubTime":"2026-08-18 17:33","pubTimestamp":1787045612,"startTime":"0","endTime":"0","summary":"Wells Fargo Initiates Scribe Therapeutics at Overweight With $60 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SCTX","PRTO","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660522468","title":"Scribe Therapeutics initiated with Early-Stage Biotech at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2660522468","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660522468?lang=en_us&edition=fundamental","pubTime":"2026-08-18 16:15","pubTimestamp":1787040911,"startTime":"0","endTime":"0","summary":"Goldman Sachs initiated coverage of Scribe Therapeutics (SCTX) with an Early-Stage Biotech rating. It believes STX-1150 “could have best of both wo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scribe-therapeutics-initiated-with-early-stage-biotech-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scribe-therapeutics-initiated-with-early-stage-biotech-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","IE0004086264.USD","LU1868836591.USD","LU0742534661.SGD","LU0106831901.USD","LU0048573561.USD","LU1868836757.USD","LU1804176565.USD","LU2237443382.USD","LU1894683348.USD","BK4588","LU1868836914.USD","LU0251142724.SGD","XBI","LU2237438978.USD","BK4552","LU2471134523.USD","BK4550","LU0345770308.USD","LU2750360641.GBP","LU2471134879.HKD","IE00B19Z3581.USD","IE0002270589.USD","LU1868837136.USD","IE00BSNM7G36.USD","IE00BFXG1179.USD","LU2237443622.USD","IE0004091025.USD","LU0251131958.USD","LU2237443465.HKD","LU2471134796.USD","BK4516","LU0868494617.USD","BK4139","LU2265009873.SGD","IE0034235188.USD","LU2237443895.HKD","LU0345770993.USD","LU1894683264.USD","LU0942090050.USD","LU1868837300.USD","BK4581","LU0868494708.USD","LU1668664300.SGD","BK4585","BK4504","LU1791807156.HKD","SCTX","GSX","LU0096364046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655744805","title":"Scribe's Genetic Editing Aims to Prevent Heart Attacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2655744805","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655744805?lang=en_us&edition=fundamental","pubTime":"2026-07-30 22:26","pubTimestamp":1785421560,"startTime":"0","endTime":"0","summary":"Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe's one-time treatments can halv","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00BJT1NW94.SGD","LU1861558580.USD","FHLC","LU1861559042.SGD","LU2023250843.SGD","CRSP","VHT","ARKG","BK4007","XLV","LU1430594728.SGD","LU2125909247.SGD","MRK","LU0238689110.USD","SG9999014575.USD","LU0006306889.USD","LU1035773651.USD","LU1066053197.SGD","PAWZ","LU2112291526.USD","LU2433249047.HKD","LU0203347892.USD","TRUH","LU0689626769.HKD","RXL","IXJ","HRTS","LU1066051225.USD","IE00BBT3K403.USD","LU2361044865.SGD","IYH","IE00B4R5TH58.HKD","BEAM","IHE","LU0058720904.USD","LU1941712264.USD","BK4534","LU1162221912.USD","IE00BN8TJ469.HKD","LU0942090050.USD","LU1201861249.SGD","PRME","SCTX","JDOC","PPH","LU1023059063.AUD","LU2360032135.SGD","SG9999014559.SGD","FTXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655846073","title":"Insiders Double Down as Big Money Pours Into Scribe Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2655846073","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655846073?lang=en_us&edition=fundamental","pubTime":"2026-07-30 10:02","pubTimestamp":1785376922,"startTime":"0","endTime":"0","summary":"New insider activity at Scribe Therapeutics Inc. ( ($SCTX) ) has taken place on July 29, 2026. Scribe Therapeutics Inc. has seen a wave of insider ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insiders-double-down-as-big-money-pours-into-scribe-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insiders-double-down-as-big-money-pours-into-scribe-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655810547","title":"OrbiMed Advisors Acquires 1,000,000 Scribe Therapeutics Shares Valued at $15 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655810547","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655810547?lang=en_us&edition=fundamental","pubTime":"2026-07-30 06:48","pubTimestamp":1785365280,"startTime":"0","endTime":"0","summary":"OrbiMed Advisors acquires 1,000,000 Scribe Therapeutics shares valued at $15 millionOrbiMed Advisors, a Scribe Therapeutics director, reported an increase in indirect common-stock holdings to 1,348,825 shares.The filing shows the acquisition of 1 million common shares at USD 15.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scribe Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL99fMsq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OrbiMed Advisors Acquires 1,000,000 Scribe Therapeutics Shares Valued at $15 Million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654967024","title":"Scribe Therapeutics CFO David Parrot Reports $ 39,990 Common Stock Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2654967024","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654967024?lang=en_us&edition=fundamental","pubTime":"2026-07-28 09:21","pubTimestamp":1785201667,"startTime":"0","endTime":"0","summary":"Scribe Therapeutics CFO David Parrot reports $ 39,990 common stock acquisitionScribe Therapeutics CFO David L. Parrot reported indirect purchases of 2,666 common shares at USD 15 each.The shares were attributed to holdings by his spouse and child, at 1,333 shares each.Parrot also reported the grant of stock options covering 227,761 shares, including 109,426 performance-based options, with exercise prices of USD 19.13 or USD 15.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scribe Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 27, 2026, and is solely responsible for","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDLc3LXvk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Scribe Therapeutics CFO David Parrot Reports $ 39,990 Common Stock Acquisition","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654254810","title":"Scribe Therapeutics Updates Governance Following Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2654254810","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654254810?lang=en_us&edition=fundamental","pubTime":"2026-07-28 05:27","pubTimestamp":1785187663,"startTime":"0","endTime":"0","summary":"The latest update is out from Scribe Therapeutics Inc. ( ($SCTX) ). On July 27, 2026, Scribe Therapeutics Inc. filed its Amended and Restated Certi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/scribe-therapeutics-updates-governance-following-initial-public-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/scribe-therapeutics-updates-governance-following-initial-public-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPOS","SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654023063","title":"Scribe Therapeutics Adopts Amended and Restated Bylaws Effective at IPO Close","url":"https://stock-news.laohu8.com/highlight/detail?id=2654023063","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654023063?lang=en_us&edition=fundamental","pubTime":"2026-07-28 05:10","pubTimestamp":1785186600,"startTime":"0","endTime":"0","summary":"Scribe Therapeutics adopts amended and restated bylaws effective at IPO closeScribe Therapeutics filed an amended and restated certificate of incorporation in Delaware on July 27, 2026.Amended and res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL2ts5V5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654040751","title":"Press Release: Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2654040751","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654040751?lang=en_us&edition=fundamental","pubTime":"2026-07-28 04:05","pubTimestamp":1785182700,"startTime":"0","endTime":"0","summary":"ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (\"Scribe Therapeutics\") (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR tech","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCTX","BK4588","SYNB","TM","03160","SPCK","BK4099","BK4555","BK4604","IPOS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654730049","title":"Opening Day: Scribe Therapeutics makes strong trading debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2654730049","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654730049?lang=en_us&edition=fundamental","pubTime":"2026-07-27 23:25","pubTimestamp":1785165946,"startTime":"0","endTime":"0","summary":"Scribe Therapeutics makes its public debut above issue price as the CRISPR drug developer opened for trading last week. The biotech entered the mar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opening-day-scribe-therapeutics-makes-strong-trading-debut-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opening-day-scribe-therapeutics-makes-strong-trading-debut-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKG","SYNB","BK4585","LU1861559042.SGD","CRSP","XBIX","BK4139","IPOS","LU1861558580.USD","SCTX","BK4556","BK4611","BK4588","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654039411","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2654039411","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654039411?lang=en_us&edition=fundamental","pubTime":"2026-07-25 01:38","pubTimestamp":1784914732,"startTime":"0","endTime":"0","summary":"Scribe Therapeutics (SCTX) has priced an upsized initial public offering of 8.6 million shares at $15 apiece, it said late Thursday.Additionally, Scribe Therapeutics agreed to sell 500,000 of its shar","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BFXG1179.USD","SCTX","NIPG","BK4588","SAFT","BK4007","SNY","BK4107","BK4108","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654039861","title":"Scribe Therapeutics Shares Rise in Nasdaq Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2654039861","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654039861?lang=en_us&edition=fundamental","pubTime":"2026-07-25 00:56","pubTimestamp":1784912164,"startTime":"0","endTime":"0","summary":"Scribe Therapeutics  shares were up sharply in their Friday debut on Nasdaq after the company priced its initial public offering of 8.58 million shares at $15.00 per share.The stock opened at $25 and was up over 50% at around $22.61 after midday.The clinical-stage biotechnology company has upsized its IPO after pricing the shares at the high end of its indicative range.It has granted its underwriters a 30-day option to purchase up to almost 1.3 million additional shares. Leerink Partners, Goldman Sachs, Guggenheim Securities and Wells Fargo Securities are joint book-running managers for the offering.Price: 22.61, Change: +7.61, Percent Change: +50.75","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LCLG","SCTX","NQmain"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}